Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)Philipp Harter, Patricia Pautier, Els Van Nieuwenhuysen, Alexander Reuss, Andres Redondo, Kristina Lindemann, Christian Kurzeder, Edgar Petru, Florian Heitz, Jalid Sehouli, Nikolaus Degregorio, Pauline Wimberger, Alexander Burges, Nadin Cron, Jonathan LedermannSee the full list of authors
30 June 2020
PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancerAnne Sophie V M van den Heerik, Nanda Horeweg, Remi A Nout, Ludy C H W Lutgens, Elzbieta M van der Steen-Banasik, G Henrike Westerveld, Hetty A van den Berg, Annerie Slot, Friederike L A Koppe, Stefan Kommoss, Jan Willem M Mens, Marlies E Nowee, Stefan Bijmolt, David Cibula, Tanja C StamSee the full list of authors
12 October 2020
Sentinel lymph node biopsy versus pelvic lymphadenectomy in early-stage cervical cancer: a multi-center randomized trial (PHENIX/CSEM 010)Hua Tu, He Huang, Bingna Xian, Jibin Li, Ping Wang, Weidong Zhao, Xiaojun Chen, Xing Xie, Chunyan Wang, Beihua Kong, Jing Xiao, Ping Zhang, Jihong Liu,
24 September 2020
DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatmentMichelle McMullen, Katherine Karakasis, Bienvenu Loembe, Emma Dean, Graem Parr, Amit M Oza
2 September 2020
A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113)Isabelle Ray-Coquard, Helen Hatcher, Emmanuelle Bompas, Antonio Casado, Annekke Westermann, Nicolas Isambert, Paolo Giovanni Casali, Sarah Pratap, Daniel Stark, Claudia Valverde, Anjana Anand, Manon Huizing, Anne Floquet, Lars Lindner, Barbara HermesSee the full list of authors
15 June 2020
A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel Lymph node Endometrial Cancer Trial)Tommaso Grassi, Andrea Mariani, David Cibula, Pamela T Soliman, Vera J Suman, Amy L Weaver, Silvana Pedra Nobre, Britta Weigelt, Gretchen E Glaser, Serena Cappuccio, Nadeem R Abu-Rustum
22 July 2020
Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE)Roni Nitecki, Jose Alejandro Rauh-Hain, Alexander Melamed, Giovanni Scambia, Rene Pareja, Robert L Coleman, Pedro T Ramirez, Anna Fagotti
20 July 2020
Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocolAnette Stolberg Kargo, Angela Coulter, Kristina Lindemann, Pernille Tine Jensen, Niels Henrik Hjøllund, Berit Jul Mosgaard, Karina Dahl Steffensen
24 June 2020
A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)Natalie YL Ngoi, Valerie Heong, Samuel Ow, Wen Yee Chay, Hee Seung Kim, Chel Hun Choi, Geraldine Goss, Jeffrey C Goh, Bee Choo Tai, Diana GZ Lim, Nivashini Kaliaperumal, Veonice B Au, John E Connolly, Jae-Weon Kim, Michael FriedlanderSee the full list of authors
25 June 2020
CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter studyJyoti Mayadev, Ana T Nunes, Mary Li, Michelle Marcovitz, Mark C Lanasa, Bradley J Monk
23 May 2020
